Kheireddin Mufti

Kheireddin Mufti

Auto-generated profile, based on publicly available information

Kheireddin Mufti

McGill University

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in Neurobiology of Aging
Verified
Journal Article
Closed access
YSYuri L. Sosero
Yuri L. Sosero
EYEric Yu
Eric Yu
LKLynne Krohn
Lynne Krohn
URUladzislau Rudakou
Uladzislau Rudakou
KMKheireddin Mufti
Kheireddin Mufti
KSKonstantin Senkevich
Konstantin Senkevich

8 April 2020 in Neurobiology of Aging
Verified
Journal Article
Closed access
BBBouchra Ouled Amar Bencheikh
Bouchra Ouled Amar Bencheikh
KSKonstantin Senkevich
Konstantin Senkevich
URUladzislau Rudakou
Uladzislau Rudakou
EYEric Yu
Eric Yu
KMKheireddin Mufti
Kheireddin Mufti
ZGZiv Gan-Or
Ziv Gan-Or

9 March 2021 in Neurology
Verified
Journal Article
Open access
PDF file
KMKheireddin Mufti
Kheireddin Mufti
EYEric Yu
Eric Yu
URUladzislau Rudakou
Uladzislau Rudakou
LKLynne Krohn
Lynne Krohn
JRJennifer A. Ruskey
Jennifer A. Ruskey
ZGZiv Gan-Or
Ziv Gan-Or
Objective To examine the role of genes identified through genome-wide association studies (GWASs) of Parkinson disease (PD) in the risk of isolated REM sleep behavior disorder (iRBD). Methods We fully sequenced 25 genes previously identified in GWASs of PD in a total of 1,039 patients with iRBD and 1,852 controls. The role of rare heterozygous variants in these genes was examined with burden tests. The contribution of biallelic variants was further tested. To examine the potential effect of rare nonsynonymous BST1 variants on the protein structure, we performed in silico structural analysis. Finally, we examined the association of common variants using logistic regression adjusted for age and sex. Results We found an association between rare heterozygous nonsynonymous variants in BST1 and iRBD (p = 0.0003 at coverage >50× and 0.0004 at >30×), driven mainly by 3 nonsynonymous variants (p.V85M, p.I101V, and p.V272M) found in 22 (1.2%) controls vs 2 (0.2%) patients. All 3 variants seem to be loss-of-function variants with a potential effect on the protein structure and stability. Rare noncoding heterozygous variants in LAMP3 were also associated with iRBD (p = 0.0006 at >30×). We found no association between rare heterozygous variants in the rest of genes and iRBD. Several carriers of biallelic variants were identified, yet there was no overrepresentation in iRBD. Conclusion Our results suggest that rare coding variants in BST1 and rare noncoding variants in LAMP3 are associated with iRBD. Additional studies are required to replicate these results and to examine whether loss of function of BST1 could be a therapeutic target.

5 November 2024 in npj Genomic Medicine
Verified
Journal Article
Open access
PDF file
KMKheireddin Mufti
Kheireddin Mufti
MCMiguel Cordova
Miguel Cordova
ESErika N. Scott
Erika N. Scott
JTJessica N. Trueman
Jessica N. Trueman
JLJessica M. Lovnicki
Jessica M. Lovnicki
BCBruce Carleton
Bruce Carleton
Vincristine-induced peripheral neuropathy is a common and highly debilitating toxicity from vincristine treatment that affects quality of life and often requires dose reduction, potentially affecting survival. Although previous studies demonstrated genetic factors are associated with vincristine neuropathy risk, the clinical relevance of most identified variants is limited by small sample sizes and unclear clinical phenotypes. A genome-wide association study was conducted in 1100 cases and controls matched by vincristine dose and genetic ancestry, uncovering a statistically significant (p < 5.0 × 10−8) variant in MCM3AP gene that substantially increases the risk of neuropathy and 12 variants protective against neuropathy within/near SPDYA, METTL8, PDE4D, FBN2, ZFAND3, NFIB, PAPPA, LRRTM3, NRG3, VTI1A, ARHGAP5, and ACTN1. A follow-up pathway analysis reveals the involvement of four key pathways, including nerve structure and development, myelination, neuronal transmission, and cytoskeleton/microfibril function pathways. These findings present potential actionable genomic markers of vincristine neuropathy and offer opportunities for tailored interventions to improve vincristine safety in children with cancer. This study is registered with ClinicalTrials.gov under the title National Active Surveillance Network and Pharmacogenomics of Adverse Drug Reactions in Children (ID NCT00414115, registered on December 21, 2006).

27 September 2020 in medRxiv
Verified
Preprint
Open access
PDF file
MEMehrdad A Estiar
Mehrdad A Estiar
EYEric Yu
Eric Yu
ISIkhlass Haj Salem
Ikhlass Haj Salem
JRJay P. Ross
Jay P. Ross
KMKheireddin Mufti
Kheireddin Mufti
ZGZiv Gan-Or
Ziv Gan-Or
Hereditary spastic paraplegia is a group of rare motor neuron diseases considered to be inherited in a classical monogenic Mendelian manner. Although the typical inheritance of spastic paraplegia type 7 is autosomal recessive, several reports have suggested that SPG7 variants may also cause autosomal dominant HSP. We aimed to conduct an exome-wide genetic analysis on a large Canadian cohort of hereditary spastic paraplegia patients and controls to examine the association of SPG7 and hereditary spastic paraplegia. In total, 585 hereditary spastic paraplegia patients from 372 families and 1,175 controls, including 580 unrelated individuals, were analyzed for the presence of SPG7 variants. Whole exome sequencing was performed on 400 hereditary spastic paraplegia patients (291 index cases) and all 1,175 controls. After excluding 38 biallelic hereditary spastic paraplegia type 7 patients, the frequency of heterozygous pathogenic/likely pathogenic SPG7 variant carriers (4.8%) among hereditary spastic paraplegia unrelated index cases who underwent WES, was significantly higher than among unrelated controls (1.7%; OR=2.88, 95%CI=1.24-6.66, p =0.009). The heterozygous SPG7 p.(Ala510Val) variant was found in 3.7% of index cases vs. 0.85% in unrelated controls (OR=4.42, 95%CI=1.49-13.07, p =0.005). We identified four heterozygous SPG7 variant carriers with an additional pathogenic variant in genes known to cause hereditary spastic paraplegia, compared to zero in controls (OR=19.58, 95%CI=1.05-365.13, p =0.0031; Fisher’s Exact test with Haldane-Anscombe correction), indicating potential digenic inheritance. We further identified four families with heterozygous variants in SPG7 and SPG7-interacting genes (CACNA1A, AFG3L2 and MORC2) . Out of these, there is especially compelling evidence for epistasis between SPG7 and AFG3L2 . The p.(Ile705Thr) variant in AFG3L2 is located at the interface between hexamer subunits, in a hotspot of mutations associated with spinocerebellar ataxia type 28 that affect its proteolytic function. Our results provide evidence for complex inheritance in SPG7-associated hereditary spastic paraplegia, which may include recessive and possibly dominant and digenic/epistasis forms of inheritance.

24 September 2020 in medRxiv
Verified
Preprint
Open access
PDF file
YSYuri L. Sosero
Yuri L. Sosero
EYEric Yu
Eric Yu
LKLynne Krohn
Lynne Krohn
URUladzislau Rudakou
Uladzislau Rudakou
KMKheireddin Mufti
Kheireddin Mufti
KSKonstantin Senkevich
Konstantin Senkevich
Background and objectives: The LRRK2 p.G2019S Parkinson’s disease (PD) variant is associated with elevated glucocerebrosidase (GCase) activity in peripheral blood. We aimed to evaluate the association of other LRRK2 variants with PD and its association with GCase activity. Methods: LRRK2 and GBA were fully sequenced in 1,123 PD patients and 576 controls from the Columbia and PPMI cohorts, in which GCase activity was measured in dried blood spots by liquid chromatography-tandem mass spectrometry. Results: LRRK2 p.M1646T was associated with increased GCase activity in the Columbia University cohort (β=1.58, p =0.0003), and increased but not significantly in the PPMI cohort (β=0.29, p= 0.58). p.M1646T was associated with PD (OR=1.18, 95%CI=1.09-1.28, p =7.33E-05) in 56,306 PD patients and proxy-cases, and 1.4 million controls. Conclusions: Our results suggest that the p.M1646T variant is associated with risk of PD with a small effect and with increased GCase activity in peripheral blood.